CYP1B1 and myocilin gene mutations in Egyptian patients with primary congenital glaucoma

Fassad, Mahmoud R; Amin, Asmaa K.; Morsy, Heba; Issa, Noha M.; Bayoumi, Nader; Shafei, Sahar A. El; Kholeif, Soha

doi:10.1016/j.ejmhg.2016.07.003

Cited by 7 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the first and third mutations (p.L432V and p.N453S) have been reported in other communities [12,14,20]; yet this is the first time to be reported in PCG affected Egyptian patients. The previously reported mutations in exon3 in PCG affected Egyptian population were P.D449D and H413_I414 delins QK P [16], N498D [21] and R368H [22]. The later three mutations were not detected in our studied patients.…”

Section: Discussioncontrasting

confidence: 51%

Cytochrome P450 Family 1 B1 Gene Mutations in Primary Congenital Glaucoma Affected Egyptian Patients

Esmael

Oraby

Nahas

2019

View full text Add to dashboard Cite

Aims: Primary congenital glaucoma (PCG) is a leading cause of childhood blindness. The cytochrome P450 family 1, subfamily B, polypeptide 1 (CYP1B1) is the most mutated gene that is associated with PCG. Very few studies have examined the promoter region and exon1 of the CYP1B1 gene. This work was planned to contribute to the description of the possible causative mutations of CYP1B1 gene that are related to PCG affected Egyptian patients. Patients and Methods: Patients diagnosed as glaucomatous based on their symptoms and detailed ophthalmological examinations at the time of presentation underwent an intraocular pressure lowering surgical procedure. Investigations were further proceeded on the molecular level. Sequencing-based mutation screen for the promoter region, exon1 and the coding region of exon3 of CYP1B1 gene have been performed in two related consanguineous PCG affected families and four other sporadic Egyptian patients using the polymerase chain reaction (PCR) assay; where PCR products were sequenced, and further analyzed. Results: Sequencing analysis revealed three novel mutations in PCG affected patients one in the promoter region (g.G2872A) and two in exon1 (g.C3268T and g.C3332T). Two additional mutations in exon3 (p.L432V and p.N453S) reported for the first time in PCG affected Egyptian patients. Clinical and genetic data of the two consanguineous families revealed that although the four parents have the same variations as their sons, they are ophthalmologically free. Conclusion: Regular ophthalmic examinations of siblings and parents of these affected patients should take place for early detection of any form of glaucoma to allow prompt diagnosis and early treatment when needed. Clinical examination and molecular genetic data could contribute to early diagnosis and prevention of the visual impairment caused by PCG. This study provides groundwork for expanded genetic investigations in Egypt paving the way for genetic counseling to help affected families make informed medical and personal decisions.

show abstract